Breast Implant Illness (BII): the evidence in 2026

What is Breast Implant Illness?

Breast Implant Illness (BII) is the term patients have given to a constellation of systemic symptoms they associate with their breast implants. There is no single FDA-approved diagnostic criterion, no specific blood test, and no formal disease classification in major medical references. But there is a meaningful, growing body of patient-reported experience — and as of 2022, the FDA includes it in implant labelling under the term "systemic symptoms commonly reported by patients."

This blog is intended to be honest about what the evidence shows and what it doesn't — without dismissing patient experience or overstating clinical certainty.

The symptoms patients report

The most-reported BII symptoms in patient communities and published surveys include:

• Fatigue — persistent, severe; not relieved by rest
• Cognitive — "brain fog," memory issues, difficulty concentrating
• Musculoskeletal — joint pain, muscle aches, fibromyalgia-like symptoms
• Autoimmune-type — Raynaud's phenomenon, thyroid abnormalities, dry eyes/mouth
• Dermatological — hair loss, rashes, skin changes
• Gastrointestinal — bloating, food sensitivities, IBS-type symptoms
• Endocrine — hormonal irregularity, weight changes
• Mood — anxiety, depression, anhedonia

These symptoms are real in the sense that they are genuinely experienced. The unresolved question in 2026 is whether breast implants are causing them — and if so, by what biological mechanism.

What does the science show?

Large epidemiological studies

Multiple large registry and cohort studies have looked at autoimmune disease incidence in women with breast implants. The findings have been inconsistent:

• Some large studies (FDA cohort, Danish registry, Mayo Clinic series) have not found a statistically significant increase in classical autoimmune diseases (lupus, rheumatoid arthritis) attributable to implants.
• Some have found small increases in specific conditions (e.g., Sjögren-like symptoms) in implant patients.
• Larger meta-analyses through 2023 generally conclude: no strong epidemiological signal for the major classical autoimmune diseases.

What this does NOT prove

The absence of a strong epidemiological signal does not necessarily mean BII is not real. There are good reasons:

• Symptoms reported by BII patients (fatigue, brain fog, joint pain) often do not meet diagnostic criteria for a classical autoimmune disease — they would not be captured in registries that count only formal diagnoses.
• The condition may affect a genetically susceptible subset of patients, diluted in large unselected populations.
• The biological mechanism may involve chronic low-grade inflammation, biofilm-mediated immune activation, or silicone fragment-driven processes that don't manifest as a classic autoimmune disease.

The explant signal

The strongest evidence in favour of BII is the self-reported improvement after explant surgery. Multiple small-to-medium studies and large patient surveys have found that:

• 50–90% of BII patients report substantial symptom improvement after explant
• Improvement is reported across the full symptom spectrum
• Symptom relief is often noted within weeks to months of explant

This is a meaningful signal — though it has limitations. Explant is not a placebo-controlled treatment, expectations are powerful, and selection bias is real. But the consistency of the signal across many independent reports is a finding that deserves serious attention.

The FDA's position in 2026

The FDA's stance on BII has evolved. As of October 2021, the FDA requires:

• A boxed warning on all breast implant packaging — the highest level of FDA caution
• A patient decision checklist that includes BII among the considerations
• Use of the term "systemic symptoms commonly reported by patients" in implant labelling — formally recognising the patient-reported experience without claiming proven causation
• Mandatory MRI surveillance recommendations for silicone implants (5–6 years post-op, then every 2–3 years)

This represents a significant shift from earlier years when the medical establishment was sometimes dismissive of BII reports.

Who might be at higher risk?

The patient-reported and emerging-research literature suggests possible risk factors, though none are confirmed:

• Personal or family history of autoimmune disease — patients with thyroid autoimmunity, Sjögren's, or undifferentiated connective tissue disease may be more susceptible
• Genetic predisposition to chronic inflammation (e.g., HLA-DRB1*04:01)
• History of multiple surgeries or implant exposure
• Some evidence for higher rates with textured surfaces, mirroring the BIA-ALCL inflammatory hypothesis — though the data is less consistent

If I'm considering breast augmentation

For women weighing the BII question before surgery, a sensible framework:

1. Honest informed consent

Your surgeon should mention BII as part of their consent process — not as a footnote, but as a recognised consideration. If a surgeon dismisses BII or refuses to discuss it, that's a sign to reconsider. Modern evidence-based aesthetic surgery includes this conversation.

2. Weight your individual risk profile

If you have a personal or strong family history of autoimmune disease, your individual risk-benefit calculation may differ from the general patient. Discuss this with both your plastic surgeon and (if relevant) your rheumatologist.

3. Know that explant is an option

Implants are not permanent commitments. If you become symptomatic, explant is a real option. En bloc capsulectomy (removing the implant with its surrounding capsule intact) is the common approach — though the marginal benefit of "en bloc" specifically vs other capsulectomy types remains debated.

4. Don't catastrophise

The majority of breast augmentation patients — millions worldwide — do not develop BII symptoms and remain happy with their decision long-term. Patient satisfaction rates are 90–95% in long-term follow-up. BII is real for a subgroup but not the typical patient experience.

If I have implants and I'm concerned

If you have implants and notice systemic symptoms:

1. See your GP first to rule out other causes — thyroid disease, anaemia, vitamin D deficiency, sleep apnoea, depression and other treatable conditions account for many "fatigue + brain fog" presentations
2. Get standard autoimmune workup — ANA, complement, thyroid panel, vitamin levels, inflammatory markers
3. Consult a board-certified plastic surgeon for an objective evaluation and to discuss explant options if needed
4. Don't be dismissed — find a surgeon who takes your symptoms seriously even if the diagnostic picture is unclear

What does Dr. Erdal do?

Dr. Erdal's approach to BII reflects current best practice:

• BII is part of standard informed consent — every patient receives written documentation acknowledging the condition
• Patient autonomy is paramount — implant choice, surface, technique are collaborative decisions
• Patients with autoimmune family history receive extended discussion and may be advised to weigh the decision more carefully
• Symptomatic implant patients are taken seriously — Dr. Erdal performs explant procedures and does not dismiss BII concerns
• Long-term follow-up means patients can reach out via WhatsApp years after surgery — including if they develop concerning systemic symptoms

The honest bottom line

BII is one of the most genuinely difficult areas in breast augmentation in 2026. The science is incomplete, the patient experience is real, and the right decision for an individual depends on her individual risk profile, her values, and her informed weighing of the trade-offs.

What it requires from a surgeon is intellectual honesty: acknowledge uncertainty, take patient experience seriously, present current evidence faithfully, and offer explant when warranted. What it requires from a patient is informed weighing: read evidence-based sources, talk with your surgeon openly, consider your personal medical history, and decide on your own terms.

Frequently asked questions